Treatment with vigabatrin carries the risk of permanent vision loss. The Food and Drug Administration (FDA) has expanded the approval of Sabril® (vigabatrin; Lundbeck) to include treatment of ...
Although its exact mechanism in the treatment of partial-onset seizures is unknown, cenobamate has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. The Food ...
Am J Health Syst Pharm. 2009;66(6):541-561. Shorvon et al. [20] conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and tolerability of levetiracetam ...
According to the Centers for Disease Control and Prevention (CDC), about 1 out of 10 people will have a seizure during their lifetime. Most of these seizures will be epileptic seizures, which are ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line results of a double-blind, placebo-controlled, Phase 3 study evaluating both the 165 mg dose and the 330 mg dose of ...
Share on Pinterest A new drug reduced seizures in subjects with treatment resistant epilepsy in a recent clinical trial. The Good Brigade/Getty Images Researchers say a new medication may potentially ...
– TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3 – “This is an exciting moment for patients, and their families, ...
Epilepsy, a condition that causes regular seizures, affects about 65 million people around the globe. Despite treatment advances, epilepsy has long posed a complicated problem to health care providers ...
Epilepsy surgery has been shown to be an effective treatment for patients with intractable epilepsy. The only randomized controlled trial conducted in this setting to date found a dramatic advantage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results